Abstract library

100 results for "urinary bladder".
#2941 Mixed Urothelial and Neuroendocrine Carcinoma of the Urinary Bladder: Case Report and Literature Review
Introduction: Neuroendocrine tumors (NETs) comprise
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mohammed Alaeddine Saidi
Authors: Saidi M A, Ghomari S
#1176 Clinical and Pathologic Characteristics of Small Cell Neuroendocrine Carcinoma of the Bladder
Introduction: Small cell carcinoma of the bladder (SCC) is a poorly differentiated neuroendocrine (NE) neoplasm accounting less than 1% of all bladder tumors, 1/3 are admixed with conventional urothelial carcinoma and hematuria is the most common clinical presentation. The unknown etiology and natural history of SCC represent a challenge for its diagnosis and treatment.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Luis Perez-Casanova
#1640 SDHB Mutation in a Young Patient with a Metastatic Paraganglioma of the Urinary Bladder
Introduction: Paragangliomas are rare tumors that arise from the sympathetic and parasympathetic ganglia that can possess an inherited trait.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: MD Ioana Maria Lambrescu
Authors: Lambrescu I M, Cima L, Leca B, Martin S, ...
#1833 Peptide Receptor Radionuclide Therapy in a Patient with SDHB Related Grade 3 Paraganglioma (PGL) of Urinary Bladder
Introduction: SDHB mutation cause aggressive metastatic PGL.36% of patients survive 5 yrs,treatment options are limited & many still being evaluated
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr Rachelle Steyn
Authors: Steyn R, Prasad V, ...
Keywords: SDHB, Bladder PGL, PRRT
#2716 Neuroendocrine Carcinoma of the Upper Urinary Tract: A Case Report
Introduction: There are no dedicated guidelines for treatment of urothelial NEC given disease rarity. An aggressive approach, including neoadjuvant cisplatin-based chemotherapy + nephroureterectomy and adjuvant platinum-based chemotherapy, is recommended.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Roberta Elisa Rossi
#2909 Serotonin-Secreting NeuroEndocrine Neoplasms of the Pancreas: Which Are the Primary Pancreatic Carcinoids?
Introduction: Serotonin-secreting pancreatic neuroendocrine neoplasms (5-HT-secreting pNENs) are very rare. They are characterised by high urinary 5-hydroxyindole-acetic acid (5-HIAA) levels (or high serum 5-HT levels).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#2967 Longitudinal Changes in Plasma 5-Hydroxyindoleacetic Acid (5-HIAA) and Other Biomarkers during Treatment of Functional Midgut Neuroendocrine Tumours (NETs) with Lanreotide Autogel: CALM NET Study Results
Introduction: CALM-NET (EudraCT 2013-002194-22; NCT02075606) evaluated pre-treatment circulating tumour cell levels in patients with NETs as a predictor of response to lanreotide autogel (LAN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Tahir Shah
Authors: Shah T, Caplin M, Khan M, Houchard A, ...
#2840 A Real-World Study of Patients with Carcinoid Syndrome at King’s College Hospital on Long-Term Telotristat Therapy
Introduction: Telotristat ethyl is a tryptophan hydroxylase inhibitor that has been shown to be effective against symptoms of carcinoid syndrome refractory to standard somatostatin analogue therapy by directly inhibiting serotonin production. While clinical trials have established short-term efficacy of the drug, we report an exploratory real-world study of 15 patients with metastatic neuroendocrine tumours on long-term Telotristat (median duration=8 months).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Doctor Shweta Hota
Authors: Hota S, Cananea E, Martin W, Clement D, ...
#2736 Second Primary Neoplasms in Patients with Neuroendocrine Neoplasms (NEN): DATA from a Retrospective Multicentric Study
Introduction: Patients with sporadic gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) may exhibit a higher risk of second primary tumors than the general population.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: dr Sara Massironi
#2746 Immunohistochemical Biomarker Expression in Gastro-Entero-Pancreatic Neuroendocrine Tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland
Introduction: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous tumor entity with respect to biological behaviour and prognosis. This makes diagnosis and treatment a major challenge.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr.med. Alexander Siebenhüner